Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Bernard Ravina sold 10,980 shares of Voyager Therapeutics stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Bernard Ravina also recently made the following trade(s):

  • On Thursday, July 20th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00.
  • On Monday, September 11th, Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock. The stock was sold at an average price of $12.87, for a total transaction of $211,968.90.
  • On Tuesday, September 5th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00.

Shares of Voyager Therapeutics, Inc. (VYGR) traded up 7.83% during midday trading on Thursday, reaching $25.88. 1,037,588 shares of the company were exchanged. Voyager Therapeutics, Inc. has a 52 week low of $8.10 and a 52 week high of $25.89. The firm has a 50-day moving average of $16.38 and a 200 day moving average of $11.46. The firm’s market capitalization is $696.25 million.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. On average, equities research analysts expect that Voyager Therapeutics, Inc. will post ($2.84) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics, Inc. (VYGR) Insider Sells $223,223.40 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/12/voyager-therapeutics-inc-vygr-insider-sells-223223-40-in-stock.html.

VYGR has been the subject of a number of recent analyst reports. Stifel Nicolaus initiated coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They set a “buy” rating and a $20.00 price target for the company. ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. BidaskClub raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. Chardan Capital reaffirmed a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. Finally, Evercore ISI initiated coverage on shares of Voyager Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Voyager Therapeutics has a consensus rating of “Buy” and an average target price of $26.29.

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its stake in Voyager Therapeutics by 57.7% during the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the period. Hershey Trust Co. boosted its stake in Voyager Therapeutics by 163.0% during the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the period. Oppenheimer & Co. Inc. purchased a new position in Voyager Therapeutics during the second quarter worth about $143,000. Rhumbline Advisers boosted its stake in Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after buying an additional 4,144 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after buying an additional 1,399 shares during the period. 40.70% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.